Search clinical trials for: BI 655130 (spesolimab)

Total 1242 results

Boehringer Ingelheim

Terminated

A Study to Test Long-term Treatment With Spesolimab in Patients With Fistulising Crohn's Disease Who Took Part in Previous Trials

Crohn Disease

Belgium, Germany, Austria, Netherlands, Korea, Republic of
Boehringer Ingelheim

Completed

Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers

Healthy

Belgium
Boehringer Ingelheim

Completed

Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers

Healthy

Belgium
Boehringer Ingelheim

Completed

Single Rising Dose Trial of Spesolimab (BI 655130) for Healthy Japanese Male Subjects

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis

Psoriasis

Taiwan, Malaysia, France, Japan, Korea, Republic of, Tunisia
Boehringer Ingelheim

Completed

Safety, Tolerability, and Pharmacokinetics of a Subcutaneous and Intravenous Dose of BI 655130 in Healthy Subjects

Healthy

Belgium
Boehringer Ingelheim

Terminated

A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032

Dermatitis, Atopic

United States, Japan, Canada
Boehringer Ingelheim

Completed

A Trial in Healthy Chinese Volunteers to Test How Different Doses of BI 655130 Are Taken up in the Body

Healthy

China
Boehringer Ingelheim

Completed

Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis

Generalized Pustular Psoriasis

United States, Singapore, Korea, Republic of, Germany, Japan, Malaysia, China, France, Thailand, Tunisia, Switzerland, Taiwan
Boehringer Ingelheim

Completed

A Study in Patients With Mild or Moderate Ulcerative Colitis Who Take a TNF Inhibitor. The Study Investigates Whether Bowel Inflammation Improves When Patients Take BI 655130 in Addition to Their Current Therapy

Colitis, Ulcerative

United Kingdom, Denmark, Germany, Spain, Netherlands, Norway
Boehringer Ingelheim

Completed

A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated

Dermatitis, Atopic

United States, Japan, Canada
Boehringer Ingelheim

Recruiting

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome

Netherton Syndrome

Belgium, United Kingdom, Australia, Germany, China, Malaysia, United States, Japan, France, Israel, Bulgaria, Italy, Switzerland, Netherlands, Portugal
Boehringer Ingelheim

Completed

A Study in Healthy People to Measure the Amount of BI 655130 in the Blood After Injecting Different Doses Into Different Parts of the Body

Healthy

Belgium
Icahn School of Medicine at Mount Sinai
Boehringer Ingelheim

Recruiting

Spesolimab in Pyoderma Gangrenosum

Pyoderma Gangrenosum

United States
Boehringer Ingelheim

Recruiting

Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States, Korea, Republic of, Israel, Spain, Australia, Japan, Italy, Germany, Denmark, Belgium, Lithuania, China, Canada, Malaysia, Singapore, New Zealand, France, Mexico, Netherlands, Greece, United Kingdom, Bulgaria, Philipp... and more
Boehringer Ingelheim

Completed

Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients

Psoriasis

Spain, Denmark, Germany, Canada, Sweden, Italy
Boehringer Ingelheim

Terminated

A Study to Test Whether Spesolimab Helps People With Crohn's Disease Who Have Symptoms of Bowel Obstruction

Fibrostenotic Crohn´s Disease

United States, Canada, Japan, Sweden
Boehringer Ingelheim

Completed

A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis

Palmoplantar Pustulosis (PPP)

United Kingdom, Korea, Republic of, United States, Canada, Belgium, Australia, Taiwan, Japan, France, Germany, Russian Federation, Hungary, Netherlands, Czechia, Poland
Boehringer Ingelheim

Completed

A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial

Hidradenitis Suppurativa

Australia, United States, Germany, Netherlands, Italy, Canada, Czechia, France, Norway, Poland, Spain
Boehringer Ingelheim

Completed

An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options

Generalized Pustular Psoriasis

China
Boehringer Ingelheim

Completed

This Study Tests How BI 655130 Works in Patients With Active Ulcerative Colitis. The Study Also Tests How Well BI 655130 is Tolerated and Whether it Helps the Patients

Colitis, Ulcerative

Belgium, Germany, United Kingdom
Pharmaceutical Research Unit, Jordan
Abdi Ibrahim Ilac San. ve Tic A.S.

Completed

Bioequivalence Pilot Study of Dirithromycin of (Abdi İbrahim İlaç San.Ve.Tic.A.Ş,Turkey) in Healthy Subjects Under Fasting Condition

Healthy

Jordan
Boehringer Ingelheim

Recruiting

A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab

Hidradenitis Suppurativa (HS)

Canada
Boehringer Ingelheim

Recruiting

PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms

Generalized Pustular Psoriasis

Japan
Boehringer Ingelheim

Terminated

A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab

Palmoplantar Pustulosis

United Kingdom, Korea, Republic of, United States, Canada, Belgium, Australia, Taiwan, Japan, France, Germany, Russian Federation, Czechia, Hungary, Poland
Boehringer Ingelheim

Completed

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

Hidradenitis Suppurativa

Norway, United States, Australia, Germany, Netherlands, Italy, Canada, Czechia, France, Poland, Spain, Belgium
Boehringer Ingelheim

Recruiting

A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares

Generalized Pustular Psoriasis

Korea, Republic of, Australia, Taiwan, Italy, Spain, Belgium, China, Malaysia, Singapore, United States, Turkey, Germany, France, Tunisia, Brazil, Thailand, India, South Africa
Boehringer Ingelheim

Completed

BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis

Colitis, Ulcerative

Spain, United Kingdom, United States, Belgium, Germany, Italy, Austria, Canada, Japan, Korea, Republic of, Russian Federation, Poland
Boehringer Ingelheim

Completed

A Study Testing How BI 655130 Works in Patients With Fistulizing Crohn's Disease

Crohn Disease

Belgium, Germany, Austria, Korea, Republic of, Netherlands, Denmark, Hungary, Spain
Boehringer Ingelheim

Completed

A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis

Generalized Pustular Psoriasis

Spain, Taiwan, Thailand, Korea, Republic of, Germany, Malaysia, United States, Argentina, Belgium, Chile, China, France, Greece, Italy, Japan, Mexico, Netherlands, Philippines, Russian Federation, South Africa, Tunisia, Turkey, Vietnam
Boehringer Ingelheim

Completed

An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options

Generalized Pustular Psoriasis

Japan
Boehringer Ingelheim

Active, not recruiting

Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study

Generalized Pustular Psoriasis

United States, Taiwan, Korea, Republic of, Germany, Malaysia, Belgium, Chile, China, France, Italy, Japan, Mexico, Philippines, Russian Federation, Spain, Thailand, Tunisia, Vietnam, Turkey, Argentina
Boehringer Ingelheim

Completed

BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis

Colitis, Ulcerative

Canada, United States, Spain, United Kingdom, Belgium, Germany, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Austria
Boehringer Ingelheim

Recruiting

A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

Melanoma | Non-small Cell Lung Cancer (NSCLC) | Carcinoma, Squamous Cell of Head and Neck (HNSCC)

Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Looks at How Food Influences the Amount of BI 1358894 in the Blood

Healthy

Germany
Boehringer Ingelheim

Withdrawn

A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer

Anal Canal Squamous Cell Carcinoma

Korea, Republic of
Boehringer Ingelheim

Active, not recruiting

A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body

Solid Tumors

Hungary
Boehringer Ingelheim

Terminated

A Study in Healthy Men to Find the Best Formulation of BI 894416 and to Test How This is Taken up in the Body

Healthy

United Kingdom
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the Body

Healthy

Netherlands
Boehringer Ingelheim

Not yet recruiting

A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity

Obesity
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects

Healthy | Asthma

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Measure the Amount of BI 730357 in the Blood When Taken as a Tablet

Healthy

Netherlands
Boehringer Ingelheim

Completed

This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.

Neoplasms | Carcinoma, Non-Small-Cell Lung

United States, Spain, United Kingdom, Canada, Poland
Boehringer Ingelheim

Terminated

A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread

Neoplasms | Carcinoma, Non-Small-Cell Lung | Neoplasm Metastasis

United States
Boehringer Ingelheim

Completed

Single Rising Dose Study With Intravenous Infusion and Subcutaneous Injection of BI 1005273 in Healthy Male Volunteers.

Healthy

Germany
Boehringer Ingelheim

Recruiting

A Study in Healthy Men to Test How Different Doses of BI 3031185 Are Tolerated and How Food Influences the Amount of BI 3031185 in the Blood

Healthy

Germany
Boehringer Ingelheim

Recruiting

IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack (IRI-EXPLORE)

Myocardial Infarction

Korea, Republic of, Germany, Spain, Hungary, United Kingdom, Italy, Canada, Australia, Poland, Slovakia, New Zealand
Boehringer Ingelheim

Recruiting

A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer

Neuroendocrine Neoplasms | Small Cell Lung Carcinoma (SCLC)

Netherlands

3

Subscribe